Clinic
Public Health Trust of Miami Dade County Florida
Public Health Trust of Miami Dade County Florida was paid $78.81M by Medicaid between Jan 2018 and Dec 2024, across 641 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 11% of everything it billed.
33Billing provider infoPUBLIC HEALTH TRUST OF MIAMI DADE COUNTY FLORIDA
MIAMI, FL 33136
MIAMI, FL 33136
33aNPI1225033020assigned 06/17/2005
33bProvider typeClinic/Center
28Total paid$78.81M
24GClaims3,111,887
24DCodes billed641
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Florida
Rank by total paid#1 of 349
Median peer was paid$95K
This provider vs. median833×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KNIGHT, MARK controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 238,127 | $5.73M | |
| 2019 | 618,076 | $19.02M | |
| 2020 | 551,425 | $12.35M | |
| 2021 | 616,172 | $12.82M | |
| 2022 | 655,910 | $15.16M | |
| 2023 | 290,561 | $9.11M | |
| 2024incomplete | 141,616 | $4.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 11% | 103,557 | 87,323 | $8.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.6% | 78,637 | 69,784 | $6.81M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.5% | 64,040 | 54,019 | $5.14M |
| 80053 | Comprehensive metabolic panel | 6.2% | 183,150 | 116,827 | $4.87M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.2% | 39,541 | 34,240 | $3.30M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.3% | 32,854 | 28,443 | $2.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 33,877 | 27,127 | $2.53M |
| G0378 | Hospital observation service, per hour | 2.8% | 40,598 | 20,710 | $2.18M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 21,851 | 19,421 | $1.64M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.7% | 3,945 | 3,747 | $1.31M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.5% | 20,876 | 17,235 | $1.18M |
| 77386 | 1.5% | 3,767 | 297 | $1.16M |
629 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 11,150 | $949K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 16,704 | $803K |
| 81003 | 1.0% | 35,112 | $800K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 5,476 | $773K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14,675 | $747K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,165 | $747K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13,511 | $744K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,968 | $740K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 12,558 | $709K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 213,922 | $678K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 56,688 | $659K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,552 | $642K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 32,344 | $636K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 727 | $634K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,664 | $620K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,060 | $604K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 1,981 | $597K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 11,400 | $563K |
| 86850 | <1% | 20,457 | $551K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,291 | $491K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,385 | $410K |
| 87799 | <1% | 23,150 | $378K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 783 | $364K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,259 | $359K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,840 | $354K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,945 | $338K |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | <1% | 2,228 | $327K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,909 | $318K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,215 | $315K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,319 | $309K |
| 86355 | <1% | 10,182 | $309K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,446 | $307K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 18,393 | $299K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,377 | $280K |
| 76770 | <1% | 3,813 | $278K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 14,417 | $276K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,068 | $261K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,604 | $251K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,032 | $250K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,548 | $245K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 8,591 | $244K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 53,672 | $241K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,296 | $239K |
| 96402 | <1% | 2,097 | $223K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 8,746 | $215K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13,795 | $205K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,318 | $204K |
| 81001 | <1% | 75,487 | $192K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,897 | $191K |
| 84100 | <1% | 41,946 | $190K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,656 | $189K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,632 | $186K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,874 | $184K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,860 | $183K |
| 96415 | <1% | 2,722 | $183K | |
| 85610 | <1% | 48,756 | $183K | |
| 83735 | <1% | 78,665 | $176K | |
| J0485 | Injection, belatacept, 1 mg | <1% | 2,005 | $173K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,675 | $172K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 5,264 | $172K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 440 | $167K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 24,046 | $164K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,037 | $162K |
| 97162 | <1% | 4,486 | $160K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,122 | $158K |
| 95819 | <1% | 1,272 | $157K | |
| 85730 | <1% | 34,523 | $157K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 31,522 | $157K |
| 77336 | <1% | 2,130 | $149K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 644 | $144K |
| 86803 | <1% | 25,421 | $140K | |
| 29705 | <1% | 2,242 | $136K | |
| 81370 | <1% | 585 | $130K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 811 | $129K |
| 84702 | <1% | 16,968 | $128K | |
| 93356 | <1% | 812 | $128K | |
| 99205 | Prolong outpt/office vis | <1% | 2,078 | $125K |
| 86900 | <1% | 20,530 | $124K | |
| 59025 | Fetal non-stress test | <1% | 2,142 | $123K |
| 73110 | <1% | 3,290 | $121K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,545 | $119K |
| 93975 | <1% | 2,203 | $119K | |
| 77300 | <1% | 221 | $119K | |
| 99201 | <1% | 1,311 | $117K | |
| 87631 | <1% | 4,097 | $116K | |
| 96416 | <1% | 1,844 | $116K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,487 | $112K |
| 82803 | <1% | 11,904 | $111K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 158 | $109K |
| 84484 | <1% | 26,844 | $102K | |
| 86833 | <1% | 13,300 | $102K | |
| 74174 | <1% | 880 | $101K | |
| 80197 | <1% | 53,944 | $101K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,079 | $100K |
| 73590 | <1% | 3,208 | $98K | |
| 93325 | <1% | 6,318 | $97K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,792 | $96K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,381 | $96K |
| J1815 | Injection, insulin, per 5 units | <1% | 12,231 | $95K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 536 | $95K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,778 | $93K |
| 0064U | <1% | 6,309 | $93K | |
| 73090 | <1% | 2,582 | $92K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13,953 | $92K |
| 86901 | <1% | 21,078 | $91K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,051 | $89K |
| 73630 | <1% | 3,193 | $84K | |
| 71045 | Radiologic examination, chest; single view | <1% | 16,153 | $83K |
| 93970 | <1% | 2,280 | $83K | |
| 73130 | <1% | 3,183 | $83K | |
| 73610 | <1% | 3,460 | $83K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,394 | $81K |
| 84132 | <1% | 9,610 | $81K | |
| 70498 | <1% | 1,234 | $80K | |
| 87186 | <1% | 9,068 | $79K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 927 | $74K |
| 76801 | <1% | 1,924 | $74K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,078 | $74K |
| 71250 | <1% | 2,122 | $71K | |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 213 | $71K |
| 76536 | <1% | 1,231 | $70K | |
| 36573 | <1% | 696 | $68K | |
| 64643 | <1% | 304 | $66K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 15,011 | $66K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,399 | $66K |
| 83690 | <1% | 22,550 | $66K | |
| 96523 | <1% | 1,779 | $65K | |
| 82330 | <1% | 12,791 | $65K | |
| 73552 | <1% | 1,660 | $61K | |
| 73140 | <1% | 1,638 | $60K | |
| 87040 | <1% | 11,400 | $60K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,192 | $57K |
| 74160 | <1% | 587 | $55K | |
| 77065 | Tomosynthesis, mammo | <1% | 877 | $55K |
| 87070 | <1% | 6,382 | $54K | |
| 93971 | <1% | 2,063 | $54K | |
| 83880 | <1% | 10,659 | $53K | |
| 87340 | <1% | 9,018 | $52K | |
| 93017 | <1% | 1,860 | $52K | |
| 36430 | <1% | 923 | $51K | |
| 80061 | Lipid panel | <1% | 22,825 | $50K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,755 | $50K |
| 73100 | <1% | 735 | $50K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,903 | $49K |
| 70496 | <1% | 380 | $48K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,438 | $48K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 9,360 | $48K |
| 73030 | <1% | 2,451 | $48K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,793 | $47K |
| 73562 | <1% | 2,842 | $47K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,753 | $45K |
| 82728 | <1% | 7,685 | $45K | |
| 0399T | <1% | 131 | $45K | |
| 70486 | <1% | 1,173 | $45K | |
| 73502 | <1% | 1,878 | $45K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,467 | $43K |
| 86832 | <1% | 13,317 | $42K | |
| 96417 | <1% | 3,572 | $42K | |
| 87497 | <1% | 19,768 | $42K | |
| 83615 | <1% | 8,553 | $42K | |
| 88342 | <1% | 3,270 | $42K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,618 | $42K |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 593 | $41K |
| 77412 | <1% | 157 | $41K | |
| 86140 | <1% | 12,220 | $41K | |
| 29075 | <1% | 714 | $40K | |
| 93282 | <1% | 787 | $40K | |
| 76642 | <1% | 1,136 | $40K | |
| 83970 | <1% | 7,535 | $40K | |
| 83550 | <1% | 4,804 | $40K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 1,341 | $40K |
| 81025 | <1% | 3,543 | $39K | |
| 85027 | <1% | 6,855 | $39K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,419 | $39K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,536 | $38K |
| 83605 | <1% | 7,973 | $38K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,852 | $38K |
| 77080 | <1% | 838 | $37K | |
| 77334 | <1% | 271 | $37K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,016 | $37K |
| 84550 | <1% | 40,118 | $37K | |
| 83540 | <1% | 7,256 | $37K | |
| 97166 | <1% | 2,906 | $36K | |
| 64642 | <1% | 333 | $36K | |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | <1% | 2,508 | $36K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,746 | $36K |
| 86780 | <1% | 3,337 | $36K | |
| 93798 | <1% | 233 | $35K | |
| 80069 | <1% | 2,476 | $35K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 30 | $35K |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 678 | $35K |
| 82947 | <1% | 11,809 | $35K | |
| 87077 | <1% | 10,491 | $35K | |
| 86359 | <1% | 10,231 | $34K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,798 | $33K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,212 | $32K |
| 87536 | <1% | 6,040 | $32K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,906 | $32K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 302 | $32K |
| 76776 | <1% | 2,285 | $32K | |
| 93281 | <1% | 709 | $32K | |
| 74018 | <1% | 1,929 | $32K | |
| 76641 | <1% | 646 | $31K | |
| 73070 | <1% | 923 | $31K | |
| 82375 | <1% | 689 | $31K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 133 | $30K |
| 88341 | <1% | 2,795 | $30K | |
| 82746 | <1% | 3,846 | $30K | |
| 96411 | <1% | 1,852 | $30K | |
| 88142 | <1% | 2,224 | $29K | |
| 85046 | <1% | 3,263 | $29K | |
| 93308 | <1% | 148 | $29K | |
| 82570 | <1% | 14,260 | $29K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,137 | $29K |
| 81376 | <1% | 626 | $29K | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 2,059 | $29K |
| 76376 | <1% | 1,069 | $28K | |
| 73080 | <1% | 1,596 | $28K | |
| 54161 | <1% | 37 | $28K | |
| 86360 | <1% | 10,164 | $28K | |
| 86235 | <1% | 7,596 | $27K | |
| 86357 | <1% | 10,190 | $27K | |
| 93350 | <1% | 152 | $27K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,847 | $26K |
| 72100 | <1% | 2,076 | $26K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,885 | $26K |
| 82784 | <1% | 11,689 | $26K | |
| 85055 | <1% | 3,037 | $25K | |
| 76820 | <1% | 1,331 | $25K | |
| 76825 | <1% | 261 | $25K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 8,271 | $25K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,173 | $25K |
| 87205 | <1% | 5,081 | $24K | |
| 82248 | <1% | 19,166 | $24K | |
| D2390 | <1% | 40 | $24K | |
| 81329 | <1% | 719 | $24K | |
| 88307 | <1% | 1,740 | $24K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 159 | $24K |
| 85007 | <1% | 6,059 | $23K | |
| 96368 | <1% | 1,615 | $23K | |
| 87210 | <1% | 2,279 | $23K | |
| 80051 | <1% | 3,094 | $23K | |
| 93320 | <1% | 4,404 | $23K | |
| 73560 | <1% | 1,073 | $21K | |
| 76870 | <1% | 462 | $21K | |
| 86787 | <1% | 4,017 | $21K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 814 | $21K |
| 82805 | <1% | 1,323 | $21K | |
| 84703 | <1% | 4,913 | $21K | |
| 82607 | <1% | 4,488 | $20K | |
| 36569 | <1% | 252 | $20K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,923 | $20K |
| 82550 | <1% | 6,152 | $20K | |
| 86703 | <1% | 11,252 | $20K | |
| 73060 | <1% | 1,426 | $20K | |
| 82378 | <1% | 2,025 | $20K | |
| 86706 | <1% | 3,215 | $20K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,155 | $20K |
| 85384 | <1% | 3,538 | $20K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 20 | $19K |
| 82435 | <1% | 7,903 | $19K | |
| 46606 | <1% | 489 | $19K | |
| 80076 | <1% | 1,605 | $19K | |
| 84439 | <1% | 3,325 | $19K | |
| 84295 | <1% | 8,065 | $19K | |
| 70491 | <1% | 180 | $18K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 613 | $18K |
| 70355 | <1% | 699 | $18K | |
| 86923 | <1% | 2,100 | $17K | |
| 31575 | <1% | 777 | $17K | |
| 12001 | <1% | 527 | $17K | |
| 86762 | <1% | 2,932 | $16K | |
| 85652 | <1% | 6,455 | $16K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 3,213 | $16K |
| 74019 | <1% | 1,480 | $16K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 509 | $16K |
| 85660 | <1% | 2,249 | $16K | |
| 88304 | <1% | 1,884 | $16K | |
| 86480 | <1% | 2,680 | $16K | |
| 82150 | <1% | 7,577 | $16K | |
| 88112 | <1% | 1,234 | $16K | |
| 93976 | <1% | 744 | $16K | |
| 93880 | <1% | 826 | $16K | |
| 72040 | <1% | 680 | $15K | |
| 92953 | <1% | 236 | $15K | |
| 83520 | <1% | 7,852 | $15K | |
| 73564 | <1% | 521 | $15K | |
| 10060 | <1% | 433 | $15K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,871 | $14K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,565 | $14K |
| 12011 | <1% | 608 | $14K | |
| 82105 | <1% | 2,681 | $14K | |
| 87075 | <1% | 1,234 | $14K | |
| 77301 | <1% | 94 | $14K | |
| 82977 | <1% | 9,575 | $14K | |
| 86828 | <1% | 2,602 | $14K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 478 | $14K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 45 | $13K |
| 93460 | <1% | 15 | $13K | |
| 92523 | <1% | 88 | $13K | |
| 72131 | <1% | 845 | $13K | |
| 72170 | <1% | 1,286 | $13K | |
| 84112 | <1% | 416 | $13K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 3,259 | $13K |
| 84155 | <1% | 9,507 | $12K | |
| 82247 | <1% | 821 | $12K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,286 | $12K |
| 90686 | <1% | 6,171 | $12K | |
| 73620 | <1% | 411 | $12K | |
| 86665 | <1% | 2,371 | $12K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,407 | $12K |
| 77338 | <1% | 120 | $12K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 317 | $12K |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 1,208 | $11K |
| 80320 | <1% | 4,486 | $11K | |
| 84153 | <1% | 1,530 | $11K | |
| 86708 | <1% | 2,057 | $11K | |
| 76813 | <1% | 285 | $11K | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 2,629 | $10K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 33 | $10K |
| 82950 | <1% | 1,317 | $10K | |
| 99152 | <1% | 1,772 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,839 | $10K |
| 19083 | <1% | 32 | $10K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 328 | $9K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 20 | $9K |
| 81401 | <1% | 629 | $9K | |
| 82043 | <1% | 6,495 | $9K | |
| 78306 | <1% | 58 | $9K | |
| 86777 | <1% | 1,881 | $9K | |
| 77001 | <1% | 222 | $8K | |
| 96376 | <1% | 1,529 | $8K | |
| 85379 | <1% | 3,650 | $8K | |
| 81243 | <1% | 1,341 | $8K | |
| 86920 | <1% | 595 | $8K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,977 | $8K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,029 | $8K |
| 80195 | <1% | 3,914 | $7K | |
| C9399 | Unclassified drugs or biologicals | <1% | 3,621 | $7K |
| 77470 | <1% | 15 | $7K | |
| 93285 | <1% | 145 | $7K | |
| 84480 | <1% | 907 | $7K | |
| 92610 | <1% | 449 | $7K | |
| 93284 | <1% | 150 | $7K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,726 | $7K |
| 87486 | <1% | 810 | $7K | |
| 73120 | <1% | 661 | $7K | |
| 86704 | <1% | 2,206 | $7K | |
| 87581 | <1% | 811 | $7K | |
| 12002 | <1% | 118 | $7K | |
| 82810 | <1% | 38 | $7K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 446 | $7K |
| 84681 | <1% | 4,549 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,265 | $6K |
| 80164 | <1% | 1,317 | $6K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 124 | $6K |
| 83020 | <1% | 997 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,887 | $6K |
| J3490 | Unclassified drugs | <1% | 2,761 | $6K |
| J8501 | Aprepitant, oral, 5 mg | <1% | 167 | $6K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,760 | $6K |
| G0008 | Administration of influenza virus vaccine | <1% | 2,373 | $6K |
| 89051 | <1% | 88 | $6K | |
| 86592 | <1% | 1,558 | $6K | |
| 86705 | <1% | 1,605 | $5K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,451 | $5K |
| 97760 | <1% | 372 | $5K | |
| 98960 | <1% | 1,546 | $5K | |
| 86644 | <1% | 1,529 | $5K | |
| 82677 | <1% | 197 | $5K | |
| 85347 | <1% | 493 | $5K | |
| 82140 | <1% | 1,103 | $5K | |
| 86778 | <1% | 1,284 | $5K | |
| 76881 | <1% | 221 | $5K | |
| 86902 | <1% | 251 | $5K | |
| 82610 | <1% | 2,461 | $5K | |
| 90715 | <1% | 5,156 | $5K | |
| 85576 | <1% | 169 | $5K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 75 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 46 | $5K |
| 82785 | <1% | 3,339 | $5K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,463 | $5K |
| 87507 | <1% | 184 | $5K | |
| 88360 | <1% | 102 | $4K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,161 | $4K |
| 74181 | <1% | 30 | $4K | |
| 84156 | <1% | 1,005 | $4K | |
| 80329 | <1% | 3,519 | $4K | |
| 86664 | <1% | 1,070 | $4K | |
| 86709 | <1% | 2,011 | $4K | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 87 | $4K |
| 86687 | <1% | 1,327 | $4K | |
| 93321 | <1% | 361 | $4K | |
| 87641 | <1% | 740 | $4K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,146 | $4K |
| 88313 | <1% | 1,424 | $4K | |
| 86663 | <1% | 1,049 | $4K | |
| 97161 | <1% | 41 | $4K | |
| 97163 | <1% | 42 | $4K | |
| 88173 | <1% | 20 | $4K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $4K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,406 | $4K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 1,030 | $4K |
| 73522 | <1% | 102 | $4K | |
| 83050 | <1% | 658 | $4K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 696 | $4K |
| 97116 | <1% | 20 | $3K | |
| 85014 | <1% | 107 | $3K | |
| 96367 | <1% | 808 | $3K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 135 | $3K |
| 29065 | <1% | 246 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,483 | $3K |
| 86038 | <1% | 757 | $3K | |
| 87116 | <1% | 172 | $3K | |
| 96401 | <1% | 26 | $3K | |
| 00840 | <1% | 245 | $3K | |
| 96158 | <1% | 108 | $3K | |
| 80169 | <1% | 1,282 | $3K | |
| 91200 | <1% | 457 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,639 | $3K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,643 | $3K |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 342 | $3K |
| 93226 | <1% | 115 | $3K | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 89 | $3K |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 101 | $3K |
| 87015 | <1% | 278 | $3K | |
| 94729 | <1% | 153 | $3K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 261 | $3K |
| J0456 | Injection, azithromycin, 500 mg | <1% | 99 | $3K |
| 87662 | <1% | 787 | $3K | |
| 76827 | <1% | 276 | $3K | |
| 86682 | <1% | 967 | $3K | |
| 86039 | <1% | 424 | $3K | |
| 00731 | <1% | 309 | $3K | |
| 73000 | <1% | 119 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 519 | $3K |
| 90750 | <1% | 625 | $3K | |
| P9021 | Red blood cells, each unit | <1% | 37 | $3K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 75 | $2K |
| 92567 | <1% | 231 | $2K | |
| 82010 | <1% | 1,005 | $2K | |
| 86301 | <1% | 658 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 544 | $2K |
| 72190 | <1% | 28 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,243 | $2K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,549 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,309 | $2K |
| 86870 | <1% | 221 | $2K | |
| 86356 | <1% | 1,535 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,002 | $2K |
| 97014 | <1% | 90 | $2K | |
| 87625 | <1% | 1,518 | $2K | |
| 72128 | <1% | 371 | $2K | |
| 86367 | <1% | 1,247 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 342 | $2K |
| 90746 | <1% | 386 | $2K | |
| 90670 | <1% | 859 | $2K | |
| 86336 | <1% | 180 | $2K | |
| 29125 | <1% | 199 | $2K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 361 | $2K |
| 36592 | <1% | 545 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 865 | $2K |
| 84134 | <1% | 597 | $2K | |
| 97167 | <1% | 12 | $2K | |
| 87102 | <1% | 94 | $2K | |
| 86701 | <1% | 407 | $2K | |
| 86790 | <1% | 584 | $2K | |
| 90732 | <1% | 709 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,299 | $2K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 317 | $2K |
| 72197 | <1% | 32 | $1K | |
| 96152 | <1% | 35 | $1K | |
| 94010 | <1% | 196 | $1K | |
| 83516 | <1% | 394 | $1K | |
| 86702 | <1% | 244 | $1K | |
| 57454 | <1% | 14 | $1K | |
| 77062 | <1% | 764 | $1K | |
| L0174 | Cervical, collar, semi-rigid, thermoplastic foam, two piece with thoracic extension, prefabricated, off-the-shelf | <1% | 84 | $1K |
| 87045 | <1% | 62 | $1K | |
| 93925 | <1% | 38 | $1K | |
| 87206 | <1% | 91 | $1K | |
| 84300 | <1% | 587 | $1K | |
| 86794 | <1% | 362 | $1K | |
| 77072 | <1% | 15 | $1K | |
| 94618 | <1% | 44 | $1K | |
| 70543 | <1% | 15 | $1K | |
| 84145 | <1% | 924 | $1K | |
| 51702 | <1% | 328 | $1K | |
| 76506 | <1% | 14 | $1K | |
| 87449 | <1% | 368 | $1K | |
| 86645 | <1% | 320 | $1K | |
| A9270 | Non-covered item or service | <1% | 1,233 | $1K |
| 47000 | <1% | 17 | $941.38 | |
| 51701 | <1% | 483 | $930.27 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 637 | $928.97 |
| 99292 | <1% | 239 | $921.82 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 555 | $913.75 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 19 | $884.66 |
| G0127 | Trimming of dystrophic nails, any number | <1% | 174 | $871.61 |
| 16020 | <1% | 74 | $839.49 | |
| 93225 | <1% | 148 | $815.57 | |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 26 | $792.41 |
| 72080 | <1% | 31 | $791.85 | |
| 84466 | <1% | 446 | $781.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 820 | $774.80 |
| 00811 | <1% | 85 | $774.20 | |
| 88300 | <1% | 565 | $766.20 | |
| 86580 | <1% | 30 | $761.95 | |
| 74022 | <1% | 74 | $753.31 | |
| 81378 | <1% | 292 | $742.28 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 44 | $741.17 |
| 82542 | <1% | 865 | $733.59 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 582 | $724.20 |
| 80074 | <1% | 15 | $713.81 | |
| 86160 | <1% | 83 | $709.84 | |
| 90734 | <1% | 206 | $706.54 | |
| 72157 | <1% | 13 | $688.60 | |
| 93304 | <1% | 15 | $687.91 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 200 | $670.17 |
| 81015 | <1% | 145 | $657.89 | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 97 | $642.24 |
| 76937 | <1% | 18 | $630.45 | |
| 80202 | <1% | 313 | $583.99 | |
| 76942 | <1% | 32 | $581.35 | |
| 43235 | <1% | 22 | $550.50 | |
| 73600 | <1% | 66 | $535.04 | |
| 86255 | <1% | 250 | $523.72 | |
| 73700 | <1% | 17 | $523.20 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 73 | $512.40 |
| 82787 | <1% | 106 | $507.09 | |
| 29405 | <1% | 15 | $494.36 | |
| 00400 | <1% | 203 | $470.80 | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 17 | $433.49 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 56 | $422.10 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 644 | $411.28 |
| 71101 | <1% | 60 | $407.23 | |
| 80185 | <1% | 60 | $402.71 | |
| 87899 | <1% | 29 | $400.05 | |
| 87640 | <1% | 711 | $399.36 | |
| 77290 | <1% | 16 | $393.09 | |
| 72072 | <1% | 17 | $368.51 | |
| 82731 | <1% | 13 | $322.44 | |
| 84146 | <1% | 21 | $315.54 | |
| 81382 | <1% | 363 | $313.14 | |
| 80177 | <1% | 177 | $304.25 | |
| 87493 | <1% | 78 | $298.46 | |
| 97130 | <1% | 29 | $292.24 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 78 | $279.97 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 347 | $278.57 |
| 87481 | <1% | 30 | $278.31 | |
| 96159 | <1% | 43 | $272.57 | |
| 86304 | <1% | 170 | $267.27 | |
| 82139 | <1% | 124 | $232.09 | |
| 83883 | <1% | 116 | $208.84 | |
| 94726 | <1% | 35 | $208.56 | |
| 93978 | <1% | 74 | $193.61 | |
| 17000 | <1% | 35 | $184.46 | |
| 97010 | <1% | 45 | $173.91 | |
| 85597 | <1% | 13 | $172.20 | |
| 87209 | <1% | 13 | $168.28 | |
| 94060 | <1% | 19 | $165.41 | |
| 84133 | <1% | 113 | $160.76 | |
| 83051 | <1% | 876 | $151.84 | |
| 92526 | <1% | 25 | $148.80 | |
| 92511 | <1% | 57 | $148.59 | |
| 36600 | <1% | 16 | $145.47 | |
| 82436 | <1% | 61 | $138.61 | |
| 86769 | <1% | 202 | $131.01 | |
| 97113 | <1% | 81 | $125.76 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 147 | $125.14 |
| 87177 | <1% | 13 | $122.96 | |
| 84436 | <1% | 134 | $111.78 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15 | $101.77 |
| 80321 | <1% | 265 | $100.98 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 106 | $96.39 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 44 | $92.62 |
| 17003 | <1% | 15 | $92.23 | |
| 83010 | <1% | 103 | $91.74 | |
| J7518 | Mycophenolic acid, oral, 180 mg | <1% | 64 | $91.25 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 54 | $90.46 |
| 84157 | <1% | 13 | $78.60 | |
| 87517 | <1% | 33 | $70.37 | |
| 87653 | <1% | 147 | $67.67 | |
| 84590 | <1% | 61 | $67.46 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 461 | $64.34 |
| 87150 | <1% | 410 | $51.99 | |
| 82652 | <1% | 51 | $50.94 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 28 | $47.16 |
| 11721 | <1% | 85 | $46.80 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 75 | $45.57 |
| 95886 | <1% | 21 | $43.81 | |
| 99151 | <1% | 63 | $42.60 | |
| 00920 | <1% | 60 | $41.37 | |
| 84446 | <1% | 34 | $41.37 | |
| 82952 | <1% | 13 | $40.69 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 45 | $32.87 |
| 77061 | <1% | 100 | $32.52 | |
| 29105 | <1% | 39 | $27.90 | |
| 69200 | <1% | 13 | $27.58 | |
| 46600 | <1% | 18 | $27.58 | |
| 83921 | <1% | 30 | $23.06 | |
| 92504 | <1% | 15 | $22.75 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 273 | $14.17 |
| 84630 | <1% | 26 | $13.79 | |
| 82951 | <1% | 13 | $6.75 | |
| 90662 | 0% | 349 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 48 | $0.00 |
| 00812 | 0% | 26 | $0.00 | |
| 84165 | 0% | 66 | $0.00 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 90 | $0.00 |
| 86334 | 0% | 22 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 33 | $0.00 |
| 82668 | 0% | 14 | $0.00 | |
| 83655 | 0% | 19 | $0.00 | |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 18 | $0.00 |
| 97129 | 0% | 30 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,093 | $0.00 |
| 95700 | 0% | 12 | $0.00 | |
| 84591 | 0% | 31 | $0.00 | |
| 86593 | 0% | 18 | $0.00 | |
| 00813 | 0% | 45 | $0.00 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 34 | $0.00 |
| 82525 | 0% | 14 | $0.00 | |
| 00790 | 0% | 16 | $0.00 | |
| 29581 | 0% | 35 | $0.00 | |
| 83789 | 0% | 22 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 22 | $0.00 |
| 90677 | 0% | 18 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKNIGHT, MARK (CHIEF FINANCIAL OFFICER)
Parent organizationPUBLIC HEALTH TRUST OF MIAMI DADE COUNTY
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.